Every rupee a business retains is a small capital-allocation decision by management. Compounding happens only when those retained rupees earn a high return. Return on Incremental Capital Employed (ROIIC) is the metric that measures exactly that — the marginal return on every new rupee of capital a business puts to work. It is arguably the single most important quality metric in value investing, and the one Warren Buffett has returned to again and again since his 1977 Fortune essay on inflation.
What Is Return on Incremental Capital Employed?
Return on Incremental Capital Employed — ROIIC — measures the additional after-tax operating profit a business generates for every additional rupee of capital it deploys over a defined period. The formula, in its simplest form, is:
ROIIC = (Change in NOPAT over period N) ÷ (Change in Capital Employed over period N−1)
Where NOPAT = Net Operating Profit After Tax, and Capital Employed = Shareholders’ Equity + Total Debt − Cash & Investments (or Fixed Assets + Net Working Capital).
The one-period lag in the denominator is deliberate: capital deployed in one year typically generates operating profits starting the following year. Most serious practitioners — Michael Mauboussin at Columbia Business School, Alice Schroeder in The Snowball, and Buffett himself — use rolling 3-, 5-, or 10-year windows to smooth out working-capital noise and one-off capex spikes.
ROIIC is fundamentally different from plain ROCE. ROCE tells you what the entire capital base is earning today — a blended number that includes both legacy assets bought decades ago and fresh rupees deployed yesterday. ROIIC isolates the marginal decision. It answers the only question that really matters for a compounder: when this business reinvests its earnings, what rate of return do those retained earnings actually earn?
Warren Buffett wrote in his 1992 shareholder letter: “Leaving the question of price aside, the best business to own is one that over an extended period can employ large amounts of incremental capital at very high rates of return. The worst business to own is one that must, or will, do the opposite — that is, consistently employ ever-greater amounts of capital at very low rates of return.” That single sentence is the architectural core of quality investing.
Why ROIIC Matters More Than Any Other Quality Metric
Compounding is not a straight line from today’s ROCE. It is a long chain of reinvestment decisions. A company earning 25% ROCE today but reinvesting retained earnings at only 8% will drift downward toward a mediocre blended return over a decade. A company earning 18% ROCE today but reinvesting every incremental rupee at 30% will drift upward, eventually producing the kind of 15–20 year wealth creation that every long-term Indian investor recognizes — Asian Paints, Pidilite, HDFC Bank in its golden decade, Page Industries, Divi’s Laboratories.
Charlie Munger’s most quoted insight from Poor Charlie’s Almanack captures this with brutal clarity: “Over the long term, it’s hard for a stock to earn a much better return than the business which underlies it earns. If the business earns 6% on capital over 40 years and you hold it for 40 years, you’re not going to make much different than a 6% return — even if you originally buy it at a huge discount. Conversely, if a business earns 18% on capital over 20 or 30 years, even if you pay an expensive-looking price, you’ll end up with a fine result.” The “return on capital” Munger is talking about — across multiple decades of reinvestment — is ROIIC, not a single-year ROCE snapshot.
Michael Mauboussin, in his 2016 research note Calculating Return on Invested Capital, showed that for a sample of 1,000+ US listed companies over 60 years, the single best predictor of shareholder returns beyond 10 years was not starting valuation, not revenue growth, not margin expansion — it was the company’s average ROIIC. Companies in the top quartile of ROIIC compounded shareholder wealth at roughly twice the rate of the bottom quartile, regardless of the starting price-to-book ratio.
For Indian investors, ROIIC is especially decisive. India is a capital-scarce, high-growth economy where every listed company has abundant reinvestment opportunities — but most destroy value while deploying them. A 2023 Credit Suisse India Equity Strategy report found that over FY13–FY23, roughly 62% of BSE-500 companies earned an ROIIC below their cost of capital. Only 19% cleared 20% ROIIC on a 10-year rolling basis. These 19% delivered almost all of India’s equity wealth creation in the period.
How the Masters Have Used ROIIC
Buffett’s entire 1972 See’s Candies acquisition thesis was an ROIIC thesis. See’s earned about $2 million on $8 million of tangible capital — a 25% pre-tax ROCE — when Berkshire bought it. Over the next 35 years, See’s generated over $1.65 billion of pre-tax earnings while requiring only about $40 million of additional capital. That is an ROIIC approaching infinity on the margin — the perfect compounding asset. The excess cash was redirected by Buffett into other investments, and those redeployed See’s earnings are now worth many tens of billions. Buffett has called See’s “the prototype of a dream business.”
Phil Fisher, in Common Stocks and Uncommon Profits (1958), listed fifteen qualitative points to identify a great growth company. Points 5 through 8 are essentially qualitative screens for high future ROIIC — margin trend, cost control, depth of management, and manufacturing efficiency. Fisher did not use the ROIIC acronym, but every question he asked was designed to determine whether the next rupee of reinvestment would earn a superior return.
Seth Klarman, in Margin of Safety (1991), added a crucial Graham-style wrinkle: even a high-ROIIC business is not automatically a good investment if the market has already priced every future rupee of retained earnings at infinity. Klarman’s discipline is to separate the assessment of business quality (ROIIC) from the assessment of price — and buy only when both align. Both questions must be answered. Most Indian investors skip the first one entirely and treat “ROCE above 15%” as a single-year pass-fail test; Klarman would call that a dangerous shortcut.
Terry Smith, founder of Fundsmith, built the best-performing global fund of the 2010s on three rules: “Buy good companies. Don’t overpay. Do nothing.” His definition of a “good company” is explicitly ROIIC-centric — he screens for businesses that earn 25%+ on incremental capital employed and can reinvest meaningfully without diluting that return. Smith has said publicly that he ignores every Indian PSU bank for exactly this reason and focuses on Indian consumer and specialty-chemical businesses that clear his ROIIC bar.
How to Calculate ROIIC on an Indian Listed Company
Here is a disciplined four-step method that any retail investor can apply using only the audited annual report and publicly available filings on the NSE or BSE website.
Step 1 — Pick a clean time window. Use at least a 5-year window, ideally 10 years. Shorter windows are contaminated by working-capital swings, one-off tax changes, and lumpy capex. Align to fiscal year-ends (31 March for Indian companies).
Step 2 — Calculate change in NOPAT. NOPAT = Operating Profit × (1 − effective tax rate). Use operating profit before interest and other income, because ROIIC is meant to measure return on capital deployed in the core business, not treasury returns. Subtract NOPAT of year 0 from NOPAT of year 5 (or year 10).
Step 3 — Calculate change in capital employed. Capital Employed = Net Fixed Assets + Investments in the business + Net Working Capital (Current Assets − Current Liabilities, excluding cash). Do not include surplus cash or non-operating investments — these are idle, not deployed. Lag the denominator by one year: if measuring NOPAT change from FY20 to FY25, use capital employed change from FY19 to FY24.
Step 4 — Divide and interpret. An ROIIC above the company’s cost of equity (typically 12–14% for Indian mid-caps, per SEBI’s 2024 study of listed-company cost-of-capital estimates) is value-creating. Below, the company is destroying value on every new rupee. Above 25% over a decade puts the company in Buffett territory. Above 40% puts it in the rarest 1% of the market.
Common Misapplications of ROIIC
Four mistakes are almost universal among retail Indian investors.
First, ignoring acquisitions and goodwill. A company that grew NOPAT by ₹100 Cr over 5 years while making ₹500 Cr of cash acquisitions did not earn 20% ROIIC — it earned 20% on acquired capital, which is entirely different from organic reinvestment. Always strip out acquired assets if you want to measure true organic compounding. Ind AS 103 disclosures help here.
Second, confusing growth with value creation. Revenue growth is not ROIIC. A PSU infrastructure company can grow revenue 15% a year for a decade while earning 4% ROIIC and destroying shareholder wealth the entire time. The market cap chart of most Indian PSU infrastructure companies over 2004–2024 is exactly this pattern.
Third, using reported operating profit without Ind AS 116 adjustments. Post-April 2019, Indian companies capitalize operating leases as right-of-use assets and lease liabilities. This inflates both EBITDA and capital employed. Be consistent: either add back lease amortization to EBITDA and strip ROU from capital employed, or keep both — but don’t mix.
Fourth, single-year ROIIC. A one-year ROIIC can be negative 50% or positive 300% depending on the timing of a single capex project. Use rolling windows. The cleanest approach is to calculate ROIIC over every overlapping 5-year window in the last 10 years — the consistency of the series tells you more than any single value.
Titan Biotech (BSE: 524717) — A Positive Case Study in Capital Deployment Discipline
This section is illustrative only and is NOT a valuation call, buy/sell/hold recommendation, or price target on Titan Biotech Limited. The numbers below are drawn from Titan Biotech’s audited FY25 disclosures and prior annual reports available on the BSE website. Investors must conduct their own due diligence.
Titan Biotech’s last decade offers a textbook set of disclosures against which a careful investor can examine the ROIIC question on an Indian small-cap. Over FY15–FY25, the company’s gross fixed assets grew from ₹11 Cr to ₹57 Cr — a capital deepening of ₹46 Cr of gross block (with an additional ₹4 Cr of CWIP as of September 2025). Over roughly the same window, the business grew revenue at a 15% CAGR and net profit at a 29% CAGR. This is exactly the shape of a business where new rupees of capital appear to be earning a return meaningfully above the cost of capital, rather than merely replacing depreciation.
The numbers below each illustrate one facet of capital-deployment discipline relevant to the ROIIC framework — they are not a valuation exercise.
| ROIIC Marker | Titan Biotech FY25 Number | What It Tells an ROIIC Analyst |
|---|---|---|
| 10-yr gross block growth | ₹11 Cr → ₹57 Cr (5.2x) | Real capital is being deployed — not just replacement capex |
| 10-yr profit CAGR | 29% | NOPAT is compounding far faster than capital — a positive ROIIC signature |
| 10-yr sales CAGR | 15% | Profit growing twice as fast as sales implies rising incremental margins on new capital |
| ROCE (FY25) | 16.9% | Blended base rate above the ~13% cost-of-equity benchmark for Indian mid-caps |
| Borrowings trajectory | ₹16 Cr (FY21) → ₹3 Cr (FY25), −81% | New capital is coming from retained earnings, not external debt — compounding is internally funded |
| CFO / Operating Profit (FY25) | 103% | The operating profit shown in ROIIC calculations is backed by actual cash — not accrual noise |
| 5-year profit CAGR | 26% | Recent ROIIC is consistent with the 10-year figure — no decay in reinvestment quality |
| Contingent liabilities | ₹7.78 Cr (5.08% of net worth), −39.7% YoY | No hidden off-balance-sheet capital risk that would distort true capital employed |
| Quarterly revenue rhythm (FY26) | Q1 ₹46.50 Cr → Q2 ₹54 Cr → Q3 ₹56 Cr | Sequential QoQ growth consistent with productive capex bearing fruit |
The pattern an ROIIC-trained investor looks for is visible in these disclosures: new capital (the incremental ₹46 Cr of gross block) has been accompanied by profit compounding at a multiple of revenue compounding, while debt has been paid down, cash conversion has stayed at or above 100% of operating profit, and off-balance-sheet risk has contracted. Each data point is consistent with — though, importantly, does not by itself prove — value-creating incremental capital deployment.
The analytically honest next step is not to conclude “Titan Biotech is undervalued” — that would violate the entire discipline of this article. The honest next step is to compute the actual ROIIC using the four-step method above, compare it to the company’s cost of equity, assess whether management’s stated reinvestment runway is credible against the segment-wise revenue breakdown (34.5% exports, 65.5% domestic), and only then — after separate work on price — form any view on action. That is a full research process, and this article is not it.
Repeat: the above is purely illustrative. No valuation call, buy/sell/hold, or price target is implied.
Key Takeaways
- ROIIC, not ROCE, is the true compounding metric. ROCE is a blended snapshot; ROIIC measures what every new rupee of retained earnings earns on the margin. Buffett, Munger, Fisher, Klarman, and Mauboussin all converge on this.
- Use rolling 5- or 10-year windows and lag the denominator by one year. Single-year ROIIC is almost always noise. Strip out acquisitions and Ind AS 116 lease distortions.
- Cross-check with cash conversion. A high ROIIC reported on accrual profits that never become cash is a classic earnings-manipulation signature. Always pair ROIIC with CFO/Operating Profit ≥ 85%.
- Titan Biotech’s FY25 disclosures — gross block expanded 5.2x over a decade, 10-year profit CAGR of 29% against 15% sales CAGR, borrowings down 81% from FY21, CFO/Operating Profit at 103% — offer a live Indian small-cap dataset an investor can use to practice this ROIIC framework, while remembering this is NOT a valuation call.
- India’s wealth creation of the last decade has come disproportionately from the ~19% of BSE-500 companies that clear 20% ROIIC on a rolling 10-year basis. The math of compounding makes ROIIC the single most important long-term filter.
Disclaimer: This article is for educational and informational purposes only. It is not investment advice, and not a buy, sell, or hold recommendation on any stock mentioned, including Titan Biotech Limited. Equity markets carry risk; please do your own research or consult a qualified professional before making investment decisions.
